title: Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population.
abstract: BACKGROUND
  To evaluate the influence of the single nucleotide polymorphism (SNP) rs 6265 in the brain-derived neurotrophic factor (BDNF) gene and 21 SNPs of the glial cell line-derived neurotrophic factor (GDNF) gene on the efficacy of paroxetine in patients with major depressive disorder (MDD).
  
  
  METHODS
  Genotyping for BDNF and GDNF polymorphisms was performed in 298 patients with MDD who started 20 mg paroxetine per day and had their plasma concentrations measured after 6 weeks. The SNPs were selected from the HapMap Chinese ethnic group and literature reports. Changes in the severity of MDD were assessed with the Hamilton Depression Rating Scale (HAM-D) at baseline and at a 6-week follow-up. Paroxetine plasma concentration was measured using high-performance liquid chromatography with fluorescence detection. The Sequenom MassArray system was used for genotyping.
  
  
  RESULTS
  At the 6-week follow-up, 219 of the 298 patients (73.5%) were responders and 79 patients (26.5%) were nonresponders to paroxetine treatment. The lower threshold concentration of paroxetine for response was 50 ng/mL, and a linear relationship was found between paroxetine plasma concentration and clinical response. The allele types for the SNPs rs 6265 (P < 0.001), rs 2973049 (P = 0.005), and rs 2216711 (P = 0.006) demonstrated significant associations with paroxetine treatment remission at week 6.
  
  
  CONCLUSIONS
  Genetic variants in the BDNF and GDNF regions may be indicators of treatment response to paroxetine in patients with MDD.
authors.affiliation: Departments of *Pharmacy; †Neurology, The First Affiliated Hospital of Anhui Medical University; and ‡Department of Pharmacy, School of Pharmacy, Anhui Medical University, Hefei, China.
authors.forename: Xin-Chen
authors.initials: XC
authors.lastname: Wang
authors.forename: Du-Juan
authors.initials: DJ
authors.lastname: Xu
authors.forename: Gui-Hai
authors.initials: GH
authors.lastname: Chen
authors.forename: Quan
authors.initials: Q
authors.lastname: Xia
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Liu
mesh_terms: D000328:Adult; D044466:Asian People; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics / Q000378:metabolism*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005838:Genotype; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000097:blood / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood / Q000627:therapeutic use
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D051100:Glial Cell Line-Derived Neurotrophic Factor; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors